Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Brooks LaboratoriesBOM:533543 +5.00%55 PS Ratio is 2.27 as of Aug. 14, 2026, which is 20% below its 10-year median of 2.84. GuruFocus rates BOM:533543 with a GF Score™ of 55/100 and a GF Value™ of ₹118.44 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 951 Drug Manufacturers companies, Brooks Laboratories ranks better than 51.31% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Brooks Laboratories's share price is ₹66.15.
Brooks Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹29.15. Hence, Brooks Laboratories's PS Ratio for today is 2.27.
The historical rank and industry rank for Brooks Laboratories's PS Ratio or its related term are showing as below:
BOM:533543'
s PS Ratio Range Over the Past 10 Years
Min: 0.42 Med: 2.84 Max: 6.64
Current: 2.27
During the past 13 years, Brooks Laboratories's highest PS Ratio was 6.64. The lowest was 0.42. And the median was 2.84.
BOM:533543's PS Ratio is ranked better than 51.31% of 951
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs BOM:533543: 2.27
Brooks Laboratories Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Brooks Laboratories was -5.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 4.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -1.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -2.00% per year.
During the past 13 years, Brooks Laboratories's highest 3-Year average Revenue per Share Growth Rate was 23.10% per year. The lowest was -41.60% per year. And the median was -0.25% per year.
Brooks Laboratories (BOM:533543) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Brooks Laboratories PS Ratio Related Terms
Brooks Laboratories PS Ratio Historical Data
* Premium members only.
The historical data trend for Brooks Laboratories's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brooks Laboratories PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's PS Ratio distribution charts can be found below:
* The bar in red indicates where Brooks Laboratories's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Brooks Laboratories's Share Price of today is ₹66.15. Brooks Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹29.15.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Brooks Laboratories (BOM:533543) has a PS Ratio of 2.27 as of Aug. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Brooks Laboratories and its competitors. This is 20% below median its historical median of 2.84. Over the past decade, Brooks Laboratories' PS Ratio has ranged from 0.42 to 6.64. According to the industry distribution chart, Brooks Laboratories ranks #463 out of 951 companies in the Drug Manufacturers industry, placing it in the top 48.7%.
Is Brooks Laboratories' PS Ratio too high?
Brooks Laboratories' current PS Ratio of 2.27 is 20% below median its 10-year median of 2.84. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 6.64. The Drug Manufacturers industry median PS Ratio is 2.33. Brooks Laboratories' value of 2.27 is 2.6% below this industry median. Based on the distribution chart, Brooks Laboratories ranks #463 out of 951 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Brooks Laboratories has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brooks Laboratories' PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Brooks Laboratories ranks #463 out of 951 companies for PS Ratio. This puts Brooks Laboratories in the upper half of its industry. The industry median PS Ratio is 2.33. Brooks Laboratories' value of 2.27 is 2.6% below this benchmark. Historically, Brooks Laboratories' own PS Ratio has ranged from 0.42 to 6.64 over the past decade. While the company's 10-year median is 2.84 vs. the industry median of 2.33, Brooks Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brooks Laboratories's current PS Ratio of 2.27 is 2.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Brooks Laboratories and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brooks Laboratories's current PS Ratio is 2.27, which is 20% below median its own 10-year median of 2.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brooks Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Brooks Laboratories (BOM:533543) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹118.44, compared to a current price of ₹66.15 — trading 44.1% below its estimated fair value. The current PS Ratio is 2.27, which is 20% below median its 10-year median of 2.84 and 2.6% below the Drug Manufacturers industry median of 2.33. Brooks Laboratories' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Brooks Laboratories (BOM:533543), the current PS Ratio is 2.27 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brooks Laboratories (BOM:533543) Overvalued in 2026?
Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued.
The current stock price of ₹66.15 is trading 44.1% below its estimated GF Value™ of ₹118.44.
GuruFocus considers Brooks Laboratories to be Significantly Undervalued.
Key valuation signals for BOM:533543:
PS Ratio: 2.27 (20% below median its 10-year median of 2.84)
GF Value™: ₹118.44 vs. price of ₹66.15 (44.1% below fair value)
Industry Position: 2.6% below the Drug Manufacturers median (#463 of 951)
No single metric tells the full story. See the BOM:533543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
55GF Score
Get the complete analysis for BOM:533543
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533543 has been successfully added to your 
